PLX4032

Showing 1 posts of 1 posts found.

Daiichi Sankyo gains rights to potential blockbuster cancer drug

March 2, 2011
Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine

Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …

The Gateway to Local Adoption Series

Latest content